Recent advances in poststroke depression

被引：88

作者：

Tharwani H.M. ^{[1
]}

Yerramsetty P. ^{[1
]}

Mannelli P. ^{[1
]}

Patkar A. ^{[1
]}

Masand P. ^{[1
]}

机构：

[1] Duke Psychiatry Specialty Clinic, Cary, NC 27518

来源：

Current Psychiatry Reports | 2007年 / 9卷 / 3期

关键词：

Mirtazapine; Nortriptyline; Trazodone; Mianserin; Reboxetine;

D O I：

10.1007/s11920-007-0023-9

中图分类号：

学科分类号：

摘要：

Depression is the most common psychiatric complication after stroke. Its prevalence varies from 20% to 80%, and it is underdiagnosed and undertreated. It has significant impact on rehabilitation, motor recovery, activities of daily living, social and interpersonal life, and mortality. Several studies have shown that biological and psychosocial factors play significant roles in the development of this disabling disease. Recent research shows that neurochemical processes also may play some role in the pathophysiology of this condition. Several trials have shown evidence that the older, as well as newer antidepressants and psychostimulants may reduce/prevent depressive symptoms after stroke. At this point there are no clear guidelines available to choose safe and effective treatments. Drugs are selected based on their efficacy and side effect profile in these patients. More research is needed to understand the pathophysiology of depression after stroke. There also is a need for more randomized clinical trials to better treat patients with this condition. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：225 / 231

页数：6

共 45 条

[1] Whyte E.M., Mulsant B.H., Post stroke depression: Epidemiology, pathophysiology, and biological treatment, Biol Psychiatry, 52, pp. 253-264, (2002)
[2] Ghose S.S., Williams L.S., Swindle R.W., Depression and other mental health diagnoses after stroke increase inpatient and outpatient medical utilization three years poststroke, Med Care, 43, pp. 1259-1264, (2005)
[3] Jia H., Damush T.M., Qin H., Et al., The impact of poststroke depression on healthcare use by veterans with acute stroke, Stroke, 37, pp. 2796-2801, (2006)
[4] Robinson R.G., Vascular depression and poststroke depression: Where do we go from here?, Am J Geriatr Psychiatry, 13, pp. 85-87, (2005)
[5] Bhogal S.K., Teasell R., Foley N., Speechley M., Heterocyclics and selective serotonin reuptake inhibitors in the treatment and prevention of poststroke depression, J Am Geriatr Soc, 53, pp. 1051-1057, (2005)
[6] Williams L.S., Ghose S.S., Swindle R.W., Depression and other mental health diagnoses increase mortality risk after ischemic stroke, Am J Psychiatry, 161, pp. 1090-1095, (2004)
[7] Carota A., Berney A., Aybek S., Et al., A prospective study of predictors of poststroke depression, Neurology, 64, pp. 428-433, (2005)
[8] Dieguez S., Staub F., Bruggimann L., Bogousslavsky J., Is poststroke depression a vascular depression?, J Neurol Sci, 226, pp. 53-58, (2004)
[9] Pohjasvaara T., Leppavuori A., Siira I., Et al., Frequency and clinical determinants of poststroke depression, Stroke, 29, pp. 2311-2317, (1998)
[10] Spalletta G., Ripa A., Caltagirone C., Symptom profile of DSM-IV major and minor depressive disorders in first-ever stroke patients, Am J Geriatr Psychiatry, 13, pp. 108-115, (2005)

← 1 2 3 4 5 →